Density and Function of Central Serotonin (5-HT) Transporters, 5-HT1A and 5-HT2A Receptors, and Effects of Their Targeting on BTBR T+tf/J Mouse Social Behavior
Overview
Authors
Affiliations
BTBR mice are potentially useful tools for autism research because their behavior parallels core social interaction impairments and restricted-repetitive behaviors. Altered regulation of central serotonin (5-HT) neurotransmission may underlie such behavioral deficits. To test this, we compared 5-HT transporter (SERT), 5-HT(1A) and 5-HT(2A) receptor densities among BTBR and C57 strains. Autoradiographic [(3) H] cyanoimipramine (1 nM) binding to SERT was 20-30% lower throughout the adult BTBR brain as compared to C57BL/10J mice. In hippocampal membrane homogenates, [(3) H] citalopram maximal binding (B(max) ) to SERT was 95 ± 13 fmol/mg protein in BTBR and 171 ± 20 fmol/mg protein in C57BL/6J mice, and the BTBR dissociation constant (K(D) ) was 2.0 ± 0.3 nM versus 1.1 ± 0.2 in C57BL/6J mice. Hippocampal 5-HT(1A) and 5-HT(2A) receptor binding was similar among strains. However, 8-OH-DPAT-stimulated [(35) S] GTPγS binding in the BTBR hippocampal CA(1) region was 28% higher, indicating elevated 5-HT(1A) capacity to activate G-proteins. In BTBR mice, the SERT blocker, fluoxetine (10 mg/kg) and the 5-HT(1A) receptor partial-agonist, buspirone (2 mg/kg) enhanced social interactions. The D(2) /5-HT(2) receptor antagonist, risperidone (0.1 mg/kg) reduced marble burying, but failed to improve sociability. Overall, altered SERT and/or 5-HT(1A) functionality in hippocampus could contribute to the relatively low sociability of BTBR mice.
Molecular Pathways, Neural Circuits and Emerging Therapies for Self-Injurious Behaviour.
Zhang K, Ibrahim G, Venetucci Gouveia F Int J Mol Sci. 2025; 26(5).
PMID: 40076564 PMC: 11900092. DOI: 10.3390/ijms26051938.
Endo N, Hiraishi A, Goto S, Nozu H, Mannari-Sasagawa T, Horii-Hayashi N Neuropsychopharmacol Rep. 2024; 45(1):e12508.
PMID: 39610036 PMC: 11660766. DOI: 10.1002/npr2.12508.
Chang C, Dai W, Hu S Psychopharmacology (Berl). 2024; 242(2):247-269.
PMID: 39158618 DOI: 10.1007/s00213-024-06670-1.
Yawata Y, Tashima R, Aritomi H, Shimada S, Onodera T, Taishi T Front Cell Neurosci. 2024; 18:1404603.
PMID: 38899227 PMC: 11185934. DOI: 10.3389/fncel.2024.1404603.
Dunham K, Khaled K, Weizman L, Venton B J Neurochem. 2024; 168(6):1097-1112.
PMID: 38323657 PMC: 11136605. DOI: 10.1111/jnc.16070.